News: ANP Antisense Therapeutics says ATL1102 for MS Phase IIb IND submitted to FDA for review, page-27

You are in denial and it would be refreshing if you stuck to discussing the company and gave some actual input rather than your usual immature comments.
Facts are the company was in such a desperate position that it is giving away 20% of its stock at historical lows for a lousy million dollars. Barely enough to cover the next 2 years of Dismonds salary.
So despite all the suggestion of licensing 1102 and 1103 out over the last 2 years it has come to this desperate grab for cash.
So much for non dilutive funding hey!